


Management of children and adult patients with atopic dermatitis

Impaired skin barrier and Th2 inflammation



1 Restoring the skin barrier

- Emollients, ointments
 - Enriched with moisturizers, lipids, ceramides
 - Wet wraps
- Vitamin D3: controversial
 - increase of cathelicidin expression in AD skin
 - Cave: topical vitamin D might induce TSLP
- Calcineurin inhibitors
 - In vitro, pimecrolimus enhances production of cathelicidin, HBD2, HBD3 by keratinocytes
- Avoid long-term therapy with topical corticosteroids

2 Avoidance of triggers

- Staph.aureus
 - Antimicrobial intervention: disinfectants, bleach baths, silver, silk clothes
 - Cave: topical antibiotics
 - vaccinations
- Soap, detergents: use syndets, oil baths
- House dust mites
 - Reduce exposure, specific immunotherapy for allergic patients
- Emotional stress

3 Anti-inflammatory therapy

- Topical:
 - Corticosteroids
 - Calcineurin inhibitors
- Systemic:
 - UV Therapy
 - Cyclosporine, corticosteroids, azathioprine, MMF, MTX
 - Alitretinoin
 - Biologics
- Proactive therapy
 - Topical corticosteroids, calcineurin inhibitors (2x per week)

4 Anti-pruritic therapy

- Emollients
 - + polidocanol (local anesthetics)
 - Wet wraps
- Effective anti-inflammatory therapy
- Antihistamines
 - Controversial
 - Non-sedating
- Cold packs
- Psychological interventions, relaxation

Educational programs

- To increase compliance
- To increase knowledge on disease pathomechanisms and treatment
- For patients and parents
- Interdisziplinäre courses: dermatologist, allergist, psychologist, nutritionist, nurse, physiotherapist (5 x 2 hours)
- Education, practical demonstrations of therapy, in AD clinic



Epidermal Role in AD Development

- Corneocyte defect—FLG, LEKTI, CDSN
- Irritants, proteases, pH change, microbes, allergens ↓
- Keratinocytes → TSLP ↓
- Influence on immune cells (Th2, IgE)
- ?Perturbs respiratory epithelium

(Zhang 2009; Demehri 2009, Irvine 2011)

AD & Atopy: New Directions in Prevention and Therapy

- Immediate barrier care in at-risk newborns: A pilot study of emollient therapy for the primary prevention of AD. *Simpson, et al. J Am Acad Dermatol 6:587-593, 2010.*
- Household peanut consumption as a risk factor for the development of peanut allergy, *Fox, et al. JACI, 123:417-23, 2009*
- Early allergen feeding: *Can early introduction of egg prevent egg allergy in infants?* *Koplin JJ, et al. JACI 126:807-13, 2010*

Preventing AD

- **Primary prevention**
 - Recognize babies genetically at risk; e.g. Ichthyosis/xerosis, family atopy
 - Alert parents to watch for irritant dermatitis
 - Treat irritant problems aggressively
- **Secondary prevention—when AD is already evident**
 - Clear with effective, remittive, topical therapy
 - Maintain remission with biw TCS, qd TCI, emollients

Hypothesis: Correcting Early Skin Barrier Dysfunction May Prevent or Delay the Development of Atopic Dermatitis

- A pilot study of emollient therapy for primary 43.4% developed eczema in the control group
 - 21.8% in the emollient group
- Incidence of eczema at 6 months (ITT)
 - OR 0.33, P <.0001



Why not recommend early emollients in atopic families?

Faulty Management Choices for AD

- Conservative TCS dosing
- Start/Stop instead of Tapering
- Diluting TCS with emollients or topical antibiotics
- Failing to pre-hydrate
- Prolonged antibiotic therapy
- Diversions from optimal therapy
 - Antihistamines
 - Allergy obsessions

Antihistamines and Childhood AD

- An indirect therapeutic aid in easing allergic comorbidities
 - Allergic rhinoconjunctivitis
- Enhancing sleep and reducing night awakenings due to itch
- A negative feature is diversion from effective topical antiinflammatory therapy
- No studies in 70 years that show an anti-pruritic effect